These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 18311666

  • 1. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG.
    Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
    [Abstract] [Full Text] [Related]

  • 2. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH, Walker BR.
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [Abstract] [Full Text] [Related]

  • 3. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
    Boyle CD, Kowalski TJ.
    Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M, Seckl JR.
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [Abstract] [Full Text] [Related]

  • 5. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, Mikhailidis DP.
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [Abstract] [Full Text] [Related]

  • 6. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW.
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [Abstract] [Full Text] [Related]

  • 7. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
    Wang M.
    Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818
    [Abstract] [Full Text] [Related]

  • 8. Recent advances in the discovery of 11beta-HSD1 inhibitors.
    Boyle CD.
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
    [Abstract] [Full Text] [Related]

  • 9. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y, Takayasu S, Nishiyama M, Tsugita M, Taguchi T, Asai M, Yoshida M, Kambayashi M, Hashimoto K.
    Mol Cell Endocrinol; 2008 Mar 26; 285(1-2):10-8. PubMed ID: 18313835
    [Abstract] [Full Text] [Related]

  • 10. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M.
    Handb Exp Pharmacol; 2011 Mar 26; (203):127-46. PubMed ID: 21484570
    [Abstract] [Full Text] [Related]

  • 11. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD, Azevedo I, Monteiro R, Martins MJ.
    Diabetes Obes Metab; 2012 Oct 26; 14(10):869-81. PubMed ID: 22321826
    [Abstract] [Full Text] [Related]

  • 12. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM.
    Mol Cell Endocrinol; 2010 Mar 25; 316(2):154-64. PubMed ID: 19804814
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
    Thieringer R, Hermanowski-Vosatka A.
    Expert Rev Cardiovasc Ther; 2005 Sep 25; 3(5):911-24. PubMed ID: 16181035
    [Abstract] [Full Text] [Related]

  • 14. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
    Alberti L, Girola A, Gilardini L, Conti A, Cattaldo S, Micheletto G, Invitti C.
    Int J Obes (Lond); 2007 Dec 25; 31(12):1826-31. PubMed ID: 17593901
    [Abstract] [Full Text] [Related]

  • 15. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ, Helmering J, Cordover D, Bowsman M, Chen M, Hale C, Fordstrom P, Zhou M, Wang M, Kaufman SA, Véniant MM.
    Diabetes Obes Metab; 2009 Jul 25; 11(7):688-99. PubMed ID: 19527482
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
    Tomlinson JW, Stewart PM.
    Nat Clin Pract Endocrinol Metab; 2005 Dec 25; 1(2):92-9. PubMed ID: 16929377
    [Abstract] [Full Text] [Related]

  • 17. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Wake DJ, Walker BR.
    Mol Cell Endocrinol; 2004 Feb 27; 215(1-2):45-54. PubMed ID: 15026174
    [Abstract] [Full Text] [Related]

  • 18. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
    Draper N, Stewart PM.
    J Endocrinol; 2005 Aug 27; 186(2):251-71. PubMed ID: 16079253
    [Abstract] [Full Text] [Related]

  • 19. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
    Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R.
    J Exp Med; 2005 Aug 15; 202(4):517-27. PubMed ID: 16103409
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
    Dhanesha N, Joharapurkar A, Shah G, Kshirsagar S, Dhote V, Sharma A, Jain M.
    Clin Exp Pharmacol Physiol; 2012 Jan 15; 39(1):69-77. PubMed ID: 22060140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.